60 citations
,
December 2015 in “Lasers in Medical Science” Low-level laser therapy is safe and can increase hair growth for male and female pattern hair loss.
33 citations
,
April 2009 in “Journal of the American College of Certified Wound Specialists” Bidirectional barbed sutures are effective and can reduce surgery time, with a low infection rate and potential cost savings despite being more expensive.
19 citations
,
August 2007 in “Seminars in Plastic Surgery” Newer skin resurfacing lasers reduce damage and scarring, with some approved for safe use and minimal side effects.
6 citations
,
October 2015 in “International Journal of Women's Dermatology” Hair aging is inevitable, but using the right hair care products can help maintain hair health.
August 2025 in “The Journal of Sexual Medicine” Finasteride, dutasteride, and silodosin have the highest risk for causing sexual dysfunction.
August 2009 in “Australian Prescriber” Dutasteride is approved to help manage prostate enlargement.
January 2026 in “Journal of Dermatological Treatment” Oral finasteride may cause more sexual side effects than expected, possibly due to negative publicity and reporting bias.
4 citations
,
September 2012 in “Clinical Pharmacology in Drug Development” Different drug doses approved in Japan and the U.S. are not mainly due to different clinical responses, and ethnic factors should be considered in setting drug doses.
2 citations
,
January 2019 in “Applied clinical research, clinical trials and regulatory affairs” Different countries have regulations to ensure the safety of hair care products, with some recalling hair straighteners due to high formaldehyde.
May 2025 in “Frontiers in Pharmacology” New treatments are needed for non-scarring alopecia due to current limitations.
February 2013 in “Journal of The American Academy of Dermatology” Using hair loss drugs finasteride and dutasteride may cause sexual side effects.
86 citations
,
January 2020 in “British Journal of Dermatology” The AA-IGA scale reliably measures treatment success in alopecia areata by considering both clinician and patient views.
3 citations
,
November 2024 in “Clinical Research” Deuruxolitinib is FDA-approved for treating severe alopecia areata.
July 2025 in “The Journal of Dermatology” Ritlecitinib has common side effects like headache and acne, and unexpected ones like diabetes and thyroid issues.
January 2018 in “Springer eBooks” Lasers are FDA-approved for permanent hair reduction, not removal, and more research is needed to improve treatments.
30 citations
,
January 2024 in “Frontiers in Pharmacology” These migraine prevention drugs can cause side effects like constipation, hair loss, injection site reactions, fatigue, and sometimes unexpected issues like Raynaud's phenomenon and weight gain.
3 citations
,
January 2015 in “Social Science Research Network” The conclusion is that off-label drug use can lead to important medical discoveries and improve patient care.
17 citations
,
May 2019 in “BMJ Open” JAK/STAT inhibitors show promise for skin diseases but aren't yet approved.
15 citations
,
March 1998 in “Journal of Public Policy & Marketing” The paper concludes that drug labels should be clear for all, especially for those with low literacy, and suggests aiming for high comprehension test passing rates with diverse test populations.
1 citations
,
January 2014 in “Side effects of drugs annual” Antihelminthic drugs treat worm infections but face challenges like low treatment coverage and potential drug resistance, with various side effects reported for different drugs.
1 citations
,
January 2005 in “Side effects of drugs annual” The document concluded that various dermatological treatments have different effectiveness and side effects, with some causing irritation, allergic reactions, or systemic effects.
The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.
182 citations
,
November 2017 in “Molecular Aspects of Medicine” The PDGF/PDGFR pathway is a potential drug target with mixed success in treating various diseases, including some cancers and fibrosis.
55 citations
,
October 2019 in “Dermatology and therapy” Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
June 2023 in “International journal of biology, pharmacy and allied sciences” New medications are improving depression treatment, emphasizing accurate diagnosis and chronic care.
25 citations
,
July 2024 in “Frontiers in Pharmacology” Rimegepant causes more nausea and skin issues, while ubrogepant causes more muscle issues; personalized treatment is important.
4 citations
,
August 2011 in “The Lancet Oncology” Off-label drug use can be risky and requires careful consideration to ensure patient safety.
September 2024 in “Annals of Medicine and Surgery” Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
1 citations
,
May 2006 in “Expert Opinion on Therapeutic Patents” No FDA-approved treatments for chemotherapy-induced hair loss existed in 2006; more research was needed.
July 2011 in “Springer eBooks” The document concluded that FDA-approved treatments like minoxidil and finasteride are effective for hair loss, while the effectiveness of natural remedies and other non-approved treatments is not well-supported by evidence.